US biopharmaceutical company Pfizer Inc (NYSE:PFE) announced on Wednesday that it has entered into an exclusive licensing agreement with biotechnology company Starna Therapeutics to develop and commercialise three preclinical in vivo chimeric antigen receptor T-cell (CAR-T) programmes targeting autoimmune diseases outside Greater China.
The agreement also grants Pfizer rights to use Starna's proprietary in vivo CAR-T technology in inflammation and immunology, as well as oncology.
Starna will receive an upfront payment of USD330m and is eligible for up to USD2.3bn in development and commercial milestone payments, in addition to royalties on net sales of approved products. Pfizer will lead clinical development outside Greater China and manufacture finished drug products for initial clinical trials at its US facilities.
Pfizer will retain exclusive commercialisation rights outside Greater China and hold options to expand its licensing territory to include the region. The agreement also provides options to exclusively license compounds developed under a separate research collaboration.
The deal expands Pfizer's Inflammation and Immunology pipeline, leveraging its expertise in RNA delivery, immunology research, clinical development and commercialisation to advance next-generation cell therapies for autoimmune diseases and cancer.
Merck launches Phase 3 trial of Ohtuvayre for COPD exacerbation prevention
Bambusa Therapeutics prices upsized initial public offering
Evogene targets acute graft-versus-host disease for AI-driven drug discovery programme
Cumberland Pharmaceuticals to submit New Drug Application for ifetroban
Alnylam reports positive Phase 1b results for brezosiran in Huntington's disease
European Commission approves Novartis' Cosentyx for polymyalgia rheumatica
AbbVie's dual-targeting Crohn's disease therapy outperforms monotherapies in Phase IIa trial
Takeda trial shows ENTYVIO reduces ulcerative colitis complication risk by nearly 70%
SciBase technology selected as primary endpoint in NIH-led skin exposure study